162 related articles for article (PubMed ID: 16896670)
21. Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma.
Houseni M; Chamroonrat W; Basu S; Bural G; Mavi A; Kumar R; Alavi A
Hell J Nucl Med; 2009; 12(1):5-9. PubMed ID: 19330173
[TBL] [Abstract][Full Text] [Related]
22. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859
[TBL] [Abstract][Full Text] [Related]
23. An input function estimation method for FDG-PET human brain studies.
Guo H; Renaut RA; Chen K
Nucl Med Biol; 2007 Jul; 34(5):483-92. PubMed ID: 17591548
[TBL] [Abstract][Full Text] [Related]
24. 18F-fluorothymidine kinetics of malignant brain tumors.
Schiepers C; Chen W; Dahlbom M; Cloughesy T; Hoh CK; Huang SC
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1003-11. PubMed ID: 17295039
[TBL] [Abstract][Full Text] [Related]
25. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
26. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
27. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
28. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
30. Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies.
Strauss LG; Pan L; Cheng C; Haberkorn U; Dimitrakopoulou-Strauss A
J Nucl Med; 2011 Mar; 52(3):379-85. PubMed ID: 21321263
[TBL] [Abstract][Full Text] [Related]
31. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
Trägårdh M; Møller N; Sørensen M
J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
[TBL] [Abstract][Full Text] [Related]
32. Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method.
Hapdey S; Buvat I; Carson JM; Carrasquillo JA; Whatley M; Bacharach SL
J Nucl Med; 2011 Apr; 52(4):634-41. PubMed ID: 21421718
[TBL] [Abstract][Full Text] [Related]
33. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
34. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
35. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
Basu S; Mahne A; Iruvuri S; Alavi A
Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
[TBL] [Abstract][Full Text] [Related]
36. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.
Westwood TD; Hogan C; Julyan PJ; Coutts G; Bonington S; Carrington B; Taylor B; Khoo S; Bonington A
Eur J Radiol; 2013 Aug; 82(8):e374-9. PubMed ID: 23578921
[TBL] [Abstract][Full Text] [Related]
37. Is liver SUV stable over time in ¹⁸F-FDG PET imaging?
Laffon E; Adhoute X; de Clermont H; Marthan R
J Nucl Med Technol; 2011 Dec; 39(4):258-63. PubMed ID: 21878481
[TBL] [Abstract][Full Text] [Related]
38. Correction for the effect of rising plasma glucose levels on quantification of MR(glc) with FDG-PET.
Dunn JT; Anthony K; Amiel SA; Marsden PK
J Cereb Blood Flow Metab; 2009 May; 29(5):1059-67. PubMed ID: 19293824
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
40. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
